- Home
- MSEX vs GHRS Comparison
MSEX vs GHRS Comparison
Compare MSEX & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MSEX | GHRS |
|---|---|---|
| Founded | 1897 | 2018 |
| Country | United States | Ireland |
| Employees | 395 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MSEX | GHRS |
|---|---|---|
| Price | $54.31 | $15.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $60.33 | $40.33 |
| AVG Volume (30 Days) | 91.1K | ★ 165.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.60 | N/A |
| Revenue Next Year | $10.94 | N/A |
| P/E Ratio | $22.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.94 | $7.98 |
| 52 Week High | $67.09 | $19.51 |
Technical Indicators
Market Signals| Indicator | MSEX | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 53.72 | 50.81 |
| Support Level | $52.36 | $11.84 |
| Resistance Level | $54.65 | $16.22 |
| Average True Range (ATR) | 1.44 | 0.82 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 49.40 | 66.67 |
Price Performance
Historical ComparisonAbout MSEX Middlesex Water Company
Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.